Sinopia’s SB-0110 Boosts Levodopa Benefit and Cuts Dyskinesia in Animal Models
Peer‑reviewed preclinical results show a trapidil‑derived compound preserved levodopa’s motor programs, lowered involuntary movements, prompting Sinopia to complete toxicology before planned first‑in‑human trials next year.
